A novel immunotherapy for dogs with osteosarcoma is discussed.
Sue Ettinger, DVM, DACVIM (Oncology)—known as Dr Sue Cancer Vet—discusses recent advancements in cancer testing for canines. The highlights include 2 new low-cost, noninvasive tests.
In an interview with dvm360®, Sue Ettinger, DVM, DACVIM (Oncology)—known as Dr Sue Cancer Vet—discusses reasons why some pet owners decline to have their dogs provided with treatment for lymphoma and how veterinarians can help clients address these challenges.
Anivive Lifesciences Inc Founder, CEO and Chairman Dylan Balsz discussed the company’s mission and how it is working to serve unmet needs in veterinary health.
In an interview with dvm360®, Sue Ettinger, DVM, DACVIM (Oncology)—Dr Sue Cancer Vet—offers insight about what to tell pet owners when their dog has been diagnosed with lymphoma.
Anivive Lifesciences' Chief Commerical Officer Chad Todd, DVM, offers insight on Laverdia-CA1, the first conditionally approved oral treatment for canine lymphoma.